Xolair ( DrugBank: - )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 1 |
| 299 | 嚢胞性線維症 | 6 |
46. 悪性関節リウマチ
臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-017306-36-NL (EUCTR) | 19/11/2010 | 19/08/2010 | ANTI-IGE THERAPY (OMALIZUMAB) IN IGE-ACPA POSITIVE RA. - TIGER | ANTI-IGE THERAPY (OMALIZUMAB) IN IGE-ACPA POSITIVE RA. - TIGER | RHEUMATOID ARTHRITIS MedDRA version: 12.1;Level: LLT;Classification code 10003268;Term: Arthritis rheumatoid | Trade Name: Xolair Product Name: OMALIZUMAB INN or Proposed INN: OMALIZUMAB Other descriptive name: Xolair | Leiden University Medical Center, Department of Rheumatology | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands |
299. 嚢胞性線維症
臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-006648-23-IE (EUCTR) | 11/12/2009 | 15/04/2009 | An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis | An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis | Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis. MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung MedDRA version: 9.1;Classification code 10000244;Term: ABPA | Trade Name: Xolair | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 4 | Belgium;Ireland;Netherlands;Germany;Italy;United Kingdom | ||
| 2 | EUCTR2007-006648-23-IT (EUCTR) | 06/08/2009 | 22/05/2009 | An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab (Xolair) in cystic fibrosis complicated by allergic bronchopulmonary aspergillosis - ND | An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab (Xolair) in cystic fibrosis complicated by allergic bronchopulmonary aspergillosis - ND | Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung | Trade Name: XOLAIR INN or Proposed INN: Omalizumab | NOVARTIS FARMA | NULL | Not Recruiting | Female: yes Male: yes | 60 | United Kingdom;Germany;Netherlands;Belgium;Ireland;Italy | |||
| 3 | EUCTR2007-006648-23-NL (EUCTR) | 08/06/2009 | 03/09/2008 | An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis | An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis | Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis. MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung MedDRA version: 9.1;Classification code 10000244;Term: ABPA | Trade Name: Xolair INN or Proposed INN: omalizumab Other descriptive name: Recombinant humanized monoclonal antibody omalizumab to IgE | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 60 | United Kingdom;Germany;Netherlands;Belgium;Ireland;Italy | |||
| 4 | EUCTR2007-006648-23-GB (EUCTR) | 27/02/2009 | 09/10/2008 | An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis | An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis | Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis. MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung MedDRA version: 9.1;Classification code 10000244;Term: ABPA | Trade Name: Xolair INN or Proposed INN: Omalizumab | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 60 | Germany;United Kingdom;Netherlands;Belgium;Ireland;Italy | |||
| 5 | EUCTR2007-006648-23-DE (EUCTR) | 12/11/2008 | 15/08/2008 | An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis | An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis | Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis. MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung MedDRA version: 9.1;Classification code 10000244;Term: ABPA | Trade Name: Xolair 150 mg Pulver und Injektionslösung zur Herstellung einer Injektionslösung Product Name: Xolair Product Code: IGE025 INN or Proposed INN: Omalizumab | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 60 | United Kingdom;Germany;Netherlands;Belgium;Ireland;Italy | |||
| 6 | EUCTR2007-006648-23-BE (EUCTR) | 30/09/2008 | 28/08/2008 | An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis | An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis | Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis. MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung MedDRA version: 9.1;Classification code 10000244;Term: ABPA | Trade Name: Xolair INN or Proposed INN: omalizumab | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 60 | United Kingdom;Germany;Netherlands;Belgium;Ireland;Italy |